CEO Executive AssistantThe antibody-drug conjugate space has compressed a decade of oncology innovation into roughly five years. Pfizer paid $43 billion for Seagen. AstraZeneca and Daiichi Sankyo committed to a development partnership worth up to $6 billion. Roche, Abbvie, BMS, and nearly every mid-size oncology biotech are either building ADC programs or acquiring the capability to do so. If you are leading a company in this space, the question is not whether ADCs deserve your personal attention. The question is how to structure that attention so it creates value rather than noise.
ADC programs are among the most time-intensive bets a CEO can make. The science sits at the intersection of biologics, small molecule chemistry, and oncology clinical development. The manufacturing demands are unlike anything in a standard biologics program. The partnership landscape is fragmented across dozens of specialized linker and payload technology holders. The regulatory environment is still evolving. And the commercial window for any given target is narrowing fast as competitors race to the same oncology indications.
This article lays out where your personal time belongs and, equally important, where it does not.
Why ADC Programs Demand Disproportionate CEO Attention
Most pipeline programs can run on delegation. You set the strategy, hire capable leadership, and insert yourself at key inflection points. ADC programs are different for three structural reasons.
First, the technical interdependencies are too consequential to leave entirely to functional leads. The choice of linker chemistry affects the payload’s therapeutic window, the conjugation process, the stability profile in circulation, and ultimately the safety signals you will need to defend to regulators. These are not independent decisions that functional teams can optimize in parallel. They feed each other, and trade-offs at any node ripple across the program. A CEO who understands the logic, even at a non-specialist level, will catch misalignments that siloed teams miss.
Second, the partnership decisions are CEO-level decisions by definition. The core IP in most ADC programs sits outside any single company. You are either licensing payload technology, linker platforms, or conjugation processes from specialists like Synaffix, Mersana, Sutro, or others. These arrangements involve multi-year exclusivity terms, milestone structures, and co-development optionality that shape your competitive position for a decade. No one else in your organization should be making those calls without you at the table.
Third, the competitive dynamics move at a pace that punishes slow strategic adjustment. If a competitor’s Phase 2 data for a HER2-targeting ADC shifts the expected efficacy bar, you need to know whether to accelerate, differentiate, or redirect resources within weeks, not quarters. That kind of judgment requires you to be close enough to the program to assess the signal quickly.
Structuring Your CMC Oversight
Chemistry, manufacturing, and controls for ADCs are genuinely hard. You are managing a multi-step bioconjugation process where each step introduces variability, and where the final product’s drug-to-antibody ratio must be tightly controlled to deliver the therapeutic window that made the molecule interesting in the first place.
You do not need to become a CMC expert. You do need a reliable early-warning system. Set up a monthly CMC review with your head of technical operations and your CMC program lead. The agenda should cover three things: current batch consistency data, any process deviations and their root cause assessments, and readiness timelines for the next regulatory submission that requires CMC data.
What you are watching for is not the detail, it is the trend. Batch-to-batch variability that is slowly widening is a signal worth interrogating before it becomes a clinical hold risk. Supply chain single points of failure for specialized starting materials deserve a CEO-level question at least once a year. And if your manufacturing partner relationship shows any signs of strain, that is a conversation you need to have directly with their leadership, not through your procurement team.
One structural decision deserves your direct input early: the build-versus-partner decision on manufacturing capability. Vertical integration of ADC manufacturing is expensive and takes years to build. Most companies at the clinical stage are better served by CDMOs with ADC-specific experience. But if your pipeline is going to include three or more ADC programs, the economics may shift. That calculation involves capital allocation, strategic risk tolerance, and your fundraising or business development narrative. It belongs to you.
Where Partnership Strategy Actually Lives
The ADC partnership landscape is one of the most complex in biopharma. You are potentially managing relationships with antibody engineering partners, payload technology licensors, linker chemistry specialists, conjugation process CDMOs, and clinical-stage co-development partners simultaneously.
The temptation is to treat this as a business development function and delegate it entirely. Resist that. The terms of your core technology access agreements determine whether you can expand your ADC pipeline to new targets, whether you can bring in co-development capital without triggering exclusivity conflicts, and whether your IP position is defensible if you go to market. Those are strategic constraints that your BD team will optimize within but cannot set.
Your role in partnership strategy has three practical components. You maintain direct executive relationships with the two or three most strategically important technology partners. You review and approve the deal terms on any agreement that creates exclusivity, sublicensing restrictions, or change-of-control provisions. And you personally sponsor the quarterly alignment conversations with any partner whose technology is on the critical path for your lead program.
The relationship maintenance piece is genuinely time-consuming and easy to deprioritize when operational demands pile up. Build it into your calendar as a protected block, not as an as-available item. These relationships are easier to maintain than to repair, and a cold relationship with your core linker licensor is a real business risk.
Navigating ADC-Specific Regulatory Complexity
ADCs occupy a genuinely novel space in the FDA’s regulatory framework. They are combination products that draw on biologics guidance, small molecule toxicology expectations, and an evolving set of ADC-specific guidance documents that the agency has been developing incrementally since the approvals of ado-trastuzumab emtansine and brentuximab vedotin.
Your regulatory strategy for an ADC program requires CEO-level engagement at several specific points. The pre-IND meeting strategy deserves your input, particularly around how you characterize the novel aspects of your linker or payload. The Phase 1 dose escalation design for ADCs requires careful thought about the safety monitoring committee charter and stopping rules, given the distinct toxicity profiles that ADCs can produce, including ocular toxicity, peripheral neuropathy, and the interstitial lung disease signals that have complicated several programs. And if you are targeting an indication where Breakthrough Therapy Designation or Accelerated Approval pathways are feasible, the decision to pursue them involves competitive timing considerations that are inherently strategic.
The FDA’s emerging guidance on ADC characterization and comparability is worth your direct attention as well. Your regulatory affairs leadership should brief you quarterly on the agency’s evolving thinking, because the standards for what constitutes an acceptable change to a validated ADC manufacturing process are still being defined. Getting that wrong at the BLA stage is a company-level event.
Sound regulatory strategy oversight is what separates programs that achieve approval on the first cycle of review from those that spend years in remediation.
Commercial Readiness in a Crowded Oncology Market
The ADC market has moved from proof-of-concept to intensely competitive in less than a decade. As of 2026, there are more than 100 ADC candidates in clinical development across the industry. The indications that attracted the earliest programs, HER2-positive breast cancer, urothelial carcinoma, and DLBCL, already have approved products setting the clinical bar.
Commercial strategy for an ADC program is not a Phase 3 problem. It is a Phase 1 problem, because the indication selection, the patient population definition, and the clinical endpoint choices you make early will determine whether you have a commercially viable product or a scientifically interesting one that fails to achieve reimbursement.
Your personal involvement in commercial strategy should focus on three questions. What is the differentiation story, and is it grounded in clinical data the payer community will accept? What is the pricing and access strategy given the competitive landscape and the healthcare systems you intend to target first? And do you have the commercial infrastructure or partnership arrangement to actually reach patients at scale?
Pipeline governance decisions sit at the heart of this: knowing when to advance, modify, or terminate an asset based on emerging competitive data is a judgment call that belongs at the CEO level.
According to McKinsey’s analysis of oncology product launches, the commercial performance gap between the top and bottom quartile of comparable launches is driven more by pre-launch positioning decisions than by post-approval execution. The time to build that positioning is now, not at NDA submission.
For a deeper look at how leading oncology CEOs structure these commercial readiness decisions, McKinsey’s research on oncology commercialization provides a useful benchmark framework.
Building the Right Internal Team Structure
The organizational design question for an ADC program is one of the more consequential decisions you will make. ADC programs require genuine cross-functional integration across biology, chemistry, manufacturing, clinical development, regulatory affairs, and commercial strategy. The standard pharma functional silo structure is poorly suited to managing those interdependencies.
Most successful ADC-focused organizations have moved toward dedicated program teams with real decision-making authority, not coordination committees that escalate everything to functional VPs. The program team model requires you to vest meaningful authority in a program leader who can make trade-off decisions across functions in real time.
Your role is to set the program team’s mandate clearly, hire the right program leader, and then protect the team’s authority from the functional organization’s natural tendency to reassert control. That protection is an ongoing CEO responsibility, not a one-time org design choice.
You also need a scientific advisory structure that gives you access to external ADC expertise. The field moves fast enough that your internal team will have knowledge gaps, and the consequences of missing a significant technical development can be severe. A standing ADC advisory board that meets quarterly and is chartered to give you direct, unfiltered input is worth the investment.
Time Allocation: A Practical Framework
Given all of the above, how should you actually allocate your time? A rough framework for a CEO with a lead ADC program in Phase 1 or 2:
Monthly: CMC review meeting (90 minutes), program team review covering clinical and translational data (2 hours), direct touchpoint with at least one key technology partner.
Quarterly: Regulatory strategy review with your head of regulatory affairs and external regulatory counsel (2 hours), commercial strategy session covering competitive landscape updates (2 hours), ADC advisory board meeting (half day), business development pipeline review covering potential new partnerships or in-licensing (2 hours).
Annually: Full strategic review of the ADC program portfolio against the competitive landscape and your capital position, with explicit decisions about resource allocation and prioritization. This is a one or two day offsite with your senior leadership team, and it should produce written decisions, not just discussion.
The total is roughly 15 to 20 hours per month of structured ADC-specific engagement, before the ad hoc demands that any active clinical program generates. That is not a small commitment. It reflects the reality that an ADC program is a bet-the-company level investment for most organizations in the space.
The Delegation Discipline
The flip side of appropriate CEO involvement is appropriate restraint. There are parts of ADC program management that should not involve you directly.
Day-to-day clinical operations, patient enrollment tactics, individual investigator relationships, site activation timelines: these belong to your clinical operations team. The detailed negotiation of CDMO service agreements below the level of strategic terms: that is your procurement and operations leadership. The technical optimization of conjugation process parameters: that is your CMC team. Trying to insert yourself into those decisions consumes time without adding value and signals a lack of confidence in your team that creates its own organizational problems.
The discipline of knowing where your judgment genuinely adds value, and where it substitutes for someone else’s expertise without improving on it, is one of the harder skills for scientifically trained CEOs to develop. ADC programs, because they are scientifically rich and high-stakes, are particularly prone to triggering that impulse. Build the discipline deliberately.
Conclusion
ADC programs are among the most demanding strategic bets in biopharma today. They require CEO-level engagement in ways that most pipeline programs do not, because the technical interdependencies, the partnership complexity, the regulatory novelty, and the commercial urgency all converge on decisions that only you are positioned to make well.
The framework is straightforward: be personally involved in CMC oversight at a strategic level, lead the partnership strategy for core technology access, engage directly with regulatory strategy at key inflection points, and drive commercial positioning from Phase 1 forward. Protect that time on your calendar as rigorously as you protect time for investor relations or board preparation. The programs that win in the ADC space will be led by CEOs who were genuinely close to the work at the moments that mattered.